Sumantha R. Sedor

Associate

Practice Description

Representative Matters

• Currently advising and representing both domestic and international pharmaceutical companies in connection with various licensing agreements, distribution and supply arrangements, joint ventures, product acquisitions, authorized generic agreements, corporate restructuring, corporate governance and other various corporate matters.
• Represented and assisted a U.S. pharmaceutical company and its international associated company in expanding its pipeline by the development and execution of a novel $500 million collaboration agreement/equity investment/line of credit transaction structure with Infinity Pharmaceuticals, Inc.
• Represented and assisted a U.S. pharmaceutical company and its international associated company in expanding its pipeline by the development and execution of a $95 million collaboration agreement/equity investment transaction structure with Novelos Therapeutics, Inc.
• Represented the largest shareholder of a publicly owned technology company in multiple PIPE financings.
• Represented a U.S. pharmaceutical company in the dissolution of a joint venture and corresponding new licensing and distribution arrangement with Par Pharmaceutical, Inc.
• Represented one of the investors in the $37 million start up financing of Optherion, Inc., a biotechnology company that is developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD).
• Represented a pharmaceutical company in the asset acquisition of a currently marketed branded product with Abbott Laboratories.
• Represented a pharmaceutical company in connection with authorized generic agreements of a currently branded product with Watson Pharmaceuticals, Inc.

Activities and Affiliations

Publications